Loading...
•
Mar 31, 2024
Immunic Q1 2024 Earnings Report
Announced financial results for the first quarter ended March 31, 2024, and provided a corporate update.
Key Takeaways
Immunic reported its Q1 2024 financial results, highlighting the advancement of its phase 2 CALLIPER trial and phase 3 ENSURE trials for vidofludimus calcium (IMU-838). The company also secured a private placement of up to $240 million, extending its cash runway into the third quarter of 2025.
Advanced phase 2 CALLIPER trial in progressive multiple sclerosis (PMS) and twin phase 3 ENSURE trials in relapsing multiple sclerosis (RMS) for vidofludimus calcium (IMU-838).
Observed separation from placebo in serum neurofilament light chain (NfL) levels in patients with PMS and non-relapsing secondary progressive multiple sclerosis (SPMS) in the phase 2 CALLIPER trial.
Expect to read-out the first of the ENSURE trials in the second quarter of 2026 and anticipate reading out the second ENSURE trial in the second half of 2026.
Bolstered balance sheet through a three-tranche private placement totaling up to $240 million, extending cash runway into the third quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...